US Patent
US11938217 — Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Formulation · Assigned to Slayback Pharma LLC · Expires 2038-10-25 · 12y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a stable, ready-to-use injectable pharmaceutical composition that combines neostigmine and glycopyrrolate with a liquid vehicle.
USPTO Abstract
Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
Drugs covered by this patent
- glycopyrrolate (Glycopyrrolate) · Yonsei University
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.